<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases</h1>
    <p class="timestamp">Published: 2013-08-28 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This is notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Peptron, Inc., a company having a place of business in Daejeon, South Korea, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/309,076, filed July 31, 2001, entitled "Long-Acting Insulinotropic Peptides and Uses Thereof" (HHS Ref. No. E-049-2001/0-US-01); ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2013-20945</p>
    <p><strong>Publication Date:</strong> 2013-08-28</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2013/08/28/2013-20945/prospective-grant-of-exclusive-patent-license-use-of-exenatide-for-the-treatment-of">https://www.federalregister.gov/documents/2013/08/28/2013-20945/prospective-grant-of-exclusive-patent-license-use-of-exenatide-for-the-treatment-of</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2013-20945</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
